Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

AxoGen, Inc. (AXGN) Makes Initial Commercial Shipment Of Avance Nerve Graft To Distributor In Italy

|Includes: AxoGen, Inc. (AXGN)

AxoGen is a regenerative medicine company focused on the development and commercialization of products and technologies for peripheral nerve reconstruction and regeneration. Peripheral nerves are very important as they provide the pathways for both motor and sensory signals throughout the body.

The company's portfolio of peripheral nerve-related products includes the Avance Nerve Graft, a allograft nerve for bridging nerve discontinuities (gaps created when nerves are severed) of 5-70 millimeters in length. By eliminating a second surgery to harvest the patient's own nerve tissue for use in the repair, the Avance Nerve Graft offers a viable alternative to traditional nerve repair procedures.

The company's portfolio also includes the AxoGuard Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and the AxoGuard Nerve Protector, a bioscaffold used to reinforce a coaptation site, wrap a partially severed nerve, or isolate and protect nerve tissue.

AxoGen announced today approval for its first commercial shipment by the Rizzoli Orthopedic Institute of the Avance Nerve Graft to its new distributor partner in Italy, MD for Life. The Rizzoli Orthopedic Institute is Italy's largest tissue bank and handles review and approval of all donors of AxoGen processed nerve allograft tissue to assure quality. The company's CEO, Karen Zaderej, spoke optimisticly about the shipment, "[It] confirms the growing demand for Avance Nerve Graft in markets outside of the United States."

For additional information about AxoGen and its portfolio of nerve-related products, please visit the company's website at

Please see disclaimer on the MissionIR website